<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7309305\results\search\disease\results.xml">
  <result pre="Structure &amp;amp; Dynamics0739-11021538-0254Taylor &amp;amp; Francis doi: 10.1080/07391102.2020.17791281779128 : Research Article" exact="Combined" post="drug repurposing and virtual screening strategies with molecular dynamics"/>
  <result pre="Tong UniversityChina[e], The CAS Key Laboratory of Innate Immunity and" exact="Chronic" post="Diseases, Hefei National Laboratory for Physical Sciences at Microscale,"/>
  <result pre="Genetics and DevelopmentChina[f], State Key Laboratory of Microbial Metabolism, Shanghai-Islamabad-Belgrade" exact="Joint" post="Innovation Center on Antibacterial Resistances, Joint Laboratory of International"/>
  <result pre="of Microbial Metabolism, Shanghai-Islamabad-Belgrade Joint Innovation Center on Antibacterial Resistances," exact="Joint" post="Laboratory of International Cooperation in Metabolic and Developmental Sciences,"/>
  <result pre="Antibacterial Resistances, Joint Laboratory of International Cooperation in Metabolic and" exact="Developmental" post="Sciences, Ministry of Education and School of Life Sciences"/>
  <result pre="4,434,653 confirmed cases and 302,169 deaths are reported. The growing" exact="infection" post="rate and death toll demand the use of all"/>
  <result pre="strategies to target 3CLpro, which has an essential role in" exact="viral" post="maturation and replication. A total of 31 FDA approved"/>
  <result pre="has an essential role in viral maturation and replication. A" exact="total" post="of 31 FDA approved anti-HIV drugs, and Traditional Chinese"/>
  <result pre="as promising hits. Furthermore, results from molecular dynamics simulation and" exact="total" post="binding free energy revealed that Saquinavir and TCM5280805 target"/>
  <result pre="TCM5280805 target the catalytic dyad (His41 and Cys145) and possess" exact="stable" post="dynamics behavior. Thus, we suggest that these compounds should"/>
  <result pre="and Technology of China National Natural Science Foundation of China" exact="Joint" post="Research Funds for Medical and Engineering Scientific Research at"/>
  <result pre="61503244), the Natural Science Foundation of Henan Province (162300410060) and" exact="Joint" post="Research Funds for Medical and Engineering and Scientific Research"/>
  <result pre="subfamily Orthocoronavirinae. However, the members of Beta-coronavirus such as severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV1 and SARS-CoV2) and the Middle"/>
  <result pre="Orthocoronavirinae. However, the members of Beta-coronavirus such as severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV1 and SARS-CoV2) and the Middle East"/>
  <result pre="However, the members of Beta-coronavirus such as severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV1 and SARS-CoV2) and the Middle East Respiratory"/>
  <result pre="respiratory syndrome coronavirus (SARS-CoV1 and SARS-CoV2) and the Middle East" exact="Respiratory" post="Syndrome Coronavirus (MERS-CoV) have been involved in pneumonia epidemics"/>
  <result pre="syndrome coronavirus (SARS-CoV1 and SARS-CoV2) and the Middle East Respiratory" exact="Syndrome" post="Coronavirus (MERS-CoV) have been involved in pneumonia epidemics in"/>
  <result pre="Middle East Respiratory Syndrome Coronavirus (MERS-CoV) have been involved in" exact="pneumonia" post="epidemics in the 21st century. SARS-CoV1, MERS-CoV and SARS-CoV2"/>
  <result pre="to every nook and cranny of the world (3.66 million" exact="infections" post="and 309774 deaths) compelled World Health Organization (WHO) to"/>
  <result pre="Commission (ICTV) on February 11, 2020, named this virus as" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). This threat of"/>
  <result pre="(ICTV) on February 11, 2020, named this virus as Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). This threat of global"/>
  <result pre="on February 11, 2020, named this virus as Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2). This threat of global concern"/>
  <result pre="February 11, 2020, named this virus as Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2). This threat of global concern to"/>
  <result pre="and design therapeutic drugs and vaccines to combat the coronavirus." exact="Infection" post="symptoms include fever, dyspnea, shortness of breath, and cough,"/>
  <result pre="shortness of breath, and cough, whereas severe cases lead to" exact="kidney failure" post="and death (Rothan &amp;amp; Byrareddy, 2020). The SARS-CoV-2 is"/>
  <result pre="receptors, inhibition of virus replication, prevention of the synthesis of" exact="viral" post="RNA and inhibition of the virus self-assembly process (Bosch"/>
  <result pre="2016). The use of these antiviral drugs is approved against" exact="viral" post="infections, and their dosages, efficacy, metabolic characteristic, and side"/>
  <result pre="subjected to High-throughput screening for potential drug molecules to combat" exact="infection" post="caused by a coronavirus (de Wilde et al., 2014;"/>
  <result pre="ten years (Khan et al., 2018; Omrani et al., 2014)." exact="Structural" post="Bioinformatics based approaches are the fastest way for finding"/>
  <result pre="inhibition is a promising target to control the recent SARS-COV-2" exact="infection" post="due to its essential role in viral maturation and"/>
  <result pre="the recent SARS-COV-2 infection due to its essential role in" exact="viral" post="maturation and replication (Ul Qamar et al., 2020). 3CLpro"/>
  <result pre="clinical treatment of novel coronavirus associated pneumonia. Materials and methods" exact="Protein" post="and ligand structure preparation Protein databank (http://www.rcsb.org/) (Rose et"/>
  <result pre="associated pneumonia. Materials and methods Protein and ligand structure preparation" exact="Protein" post="databank (http://www.rcsb.org/) (Rose et al., 2016) was used for"/>
  <result pre="approach was fruitful in the case of sildenafil for leprosy," exact="erectile dysfunction," post="and pulmonary hypertension, and multiple myeloma thalidomide (Hernandez et"/>
  <result pre="in the case of sildenafil for leprosy, erectile dysfunction, and" exact="pulmonary" post="hypertension, and multiple myeloma thalidomide (Hernandez et al., 2017)."/>
  <result pre="of sildenafil for leprosy, erectile dysfunction, and pulmonary hypertension, and" exact="multiple myeloma" post="thalidomide (Hernandez et al., 2017). Literature mining was carried"/>
  <result pre="sildenafil for leprosy, erectile dysfunction, and pulmonary hypertension, and multiple" exact="myeloma" post="thalidomide (Hernandez et al., 2017). Literature mining was carried"/>
  <result pre="out to collect anti-HIV drugs for screening against 3CLpro (SARS-COV-2)." exact="Multiple" post="drugs were retrieved from drugbank database. A total of"/>
  <result pre="3CLpro (SARS-COV-2). Multiple drugs were retrieved from drugbank database. A" exact="total" post="of 31 drugs were shortlisted for screening against the"/>
  <result pre="values were set and also for short-range Columbic, respectively. A" exact="total" post="of 100â€‰ns MD simulation was performed with a time"/>
  <result pre="g a n d ] In this equation, Î&quot;Gbind represents" exact="total" post="free binding energy, while others show the free energy"/>
  <result pre="(SARS-COV-2). Drug Name Drugbank ID Targeted virus(es) HIV-1 HIV-II HBV" exact="HTLV-1" post="Enfuvirtide DB00109 âœ&quot; X X X Nelfinavir DB00220 âœ&quot;"/>
  <result pre="virtual screening of the Traditional Chinese medicines database (TCM). A" exact="total" post="of 37,800 compounds were screened after excluding the drugs"/>
  <result pre="5,6-Dihydroxyflavone, 6,7-Dihydroxyflavone, Chrysin, Herbacetin and Baicalein which are flavonoids and" exact="testes" post="to have strong inhibitory effects in an experimental condition"/>
  <result pre="the six systems was calculated by using Root Mean Square" exact="Deviation" post="(RMSD). We tested the stability of the docked drugs"/>
  <result pre="system. The results suggest that all the six systems were" exact="stable" post="with acceptable deviation (as shown in Figure 4). The"/>
  <result pre="showed a slight deviation between 40 and 45ns but remained" exact="stable" post="during the course of the simulation. Figure 4. RMSDs"/>
  <result pre="rest of the simulation time. Thus, these results revealed the" exact="stable" post="internal motions and negligible fluctuations during the course of"/>
  <result pre="ligand at different time intervals. Also, the systems with more" exact="stable" post="behaviour show that the ligand remained intact, and the"/>
  <result pre="is almost similar and was recorded around 1â€&quot;4Ã… in all" exact="secondary" post="components except loop regions with slightly fluctuated residues. However,"/>
  <result pre="regions with slightly fluctuated residues. However, active site residues seem" exact="stable" post="in the course of the simulation, which is due"/>
  <result pre="system 3CLpro-5280343 wed higher fluctuation than the rest, but the" exact="residual" post="flexibility pattern was similar. The average RMSF for all"/>
  <result pre="and this both correlated and non-correlated motions are affected. The" exact="secondary" post="structure components are also given in Figure 5 (Right"/>
  <result pre="shows the RMSF in Ã…. The right panel shows the" exact="secondary" post="structure of 3CLpro. Radius of gyration The radius of"/>
  <result pre="gyration The radius of Gyration (RoG) conveys the information of" exact="stable" post="and unstable folding protein while interacting with ligands. Less"/>
  <result pre="frames was observed, but soon after 3500, the values become" exact="lower" post="and uniform. In the case of 3CLpro-5280805, 3CLpro-5280445, 3CLpro-5280863,"/>
  <result pre="energy, polar solvation energy, solvent accessible surface area energy, and" exact="total" post="binding free energy of all the systems are given"/>
  <result pre="can be seen that the 3CLpro-Saquinavir system possesses the highest" exact="total" post="binding energy of âˆ’74.4061â€‰kcal/mol. Thus it confirms that Saquinavir,"/>
  <result pre="by adding 5-folds more simulation time. Table 3. Shows the" exact="total" post="binding free energy and related term of all the"/>
  <result pre="to MMGBSA analysis. All the energies are given in kcal/mol/." exact="Complex" post="name MMGBSA Î&quot;vdW Î&quot;elec Î&quot;ps Î&quot;SASA Î&quot;G total 3CLpro-Saquinavir"/>
  <result pre="in kcal/mol/. Complex name MMGBSA Î&quot;vdW Î&quot;elec Î&quot;ps Î&quot;SASA Î&quot;G" exact="total" post="3CLpro-Saquinavir âˆ’80.2350 0.0000 13.7916 âˆ’7.9627 âˆ’74.4061 3CLpro-5280805 âˆ’10.595 âˆ’26.061"/>
  <result pre="surface area energy; vdW = van der Waals energy; G" exact="Total" post="= total binding free energy; MMGBSA = molecular mechanics"/>
  <result pre="energy; vdW = van der Waals energy; G Total =" exact="total" post="binding free energy; MMGBSA = molecular mechanics generalized Born"/>
  <result pre="docking score and interaction. Herein, TCM5280805 also possesses the best" exact="total" post="binding energy,29.486â€‰kcal/mol, against the 3CLpro. Also, the other hits"/>
  <result pre="other hits from including TCM5280445, TCM5280343, TCM5280863, and TCM5458190 possess" exact="total" post="binding energy of âˆ’16.342â€‰kcal/mol, âˆ’17.184â€‰kcal/mol, âˆ’10.315â€‰kcal/mol and âˆ’15.695â€‰kcal/mol. While"/>
  <result pre="experimentally against the SARS-COV-2 at earliest. Discussion To date, a" exact="total" post="of 4,434,653 confirmed cases and 302,169 deaths are reported"/>
  <result pre="reported from the SARS-COV-2 epidemic, which indicates that the current" exact="viral" post="treatment is not satisfactory, and more diverse studies are"/>
  <result pre="of SARS-COV-2. Further, our existing capacity for treating zoonotic coronavirus" exact="infections" post="is still in the trial, and the available resources"/>
  <result pre="still in the trial, and the available resources seem very" exact="limited" post="to fight this life-threatening hazard. Although extensive research efforts"/>
  <result pre="towards disease-oriented development (Pushpakom et al., 2019). One of the" exact="primary" post="reasons why no prototype coronavirus inhibitor has progressed to"/>
  <result pre="the (early) preclinical stage so far is due to the" exact="transient" post="nature of this epidemic. Like the SARS virus 17â€‰years"/>
  <result pre="broad-spectrum inhibitors that can reduce the symptoms of human coronavirus" exact="infection" post="remains a formidable subject of study. Considering the time-consuming"/>
  <result pre="diseases may be the only fastest therapeutic choice for emerging" exact="infectious diseases." post="The prescription has ample experience and dosage for most"/>
  <result pre="the treatment of SARS-COV-2 because of its role in the" exact="viral" post="replication cycle. The current study focused on structure based"/>
  <result pre="coronavirus spike protein is a class I virus fusion protein:" exact="Structural" post="and functional characterization of the fusion core complex. Journal"/>
  <result pre="&amp;amp; YuenK.-Y. (2013). Broad-spectrum antivirals for the emerging Middle East" exact="respiratory" post="syndrome coronavirus. The Journal of Infection, 67(6), 606â€&quot;616. 10.1016/j.jinf.2013.09.02924096239"/>
  <result pre="YuenK.-Y. (2013). Broad-spectrum antivirals for the emerging Middle East respiratory" exact="syndrome" post="coronavirus. The Journal of Infection, 67(6), 606â€&quot;616. 10.1016/j.jinf.2013.09.02924096239 ChenF.,"/>
  <result pre="ChengV. C., LauS. K., WooP. C., &amp;amp; YuenK. Y. (2007)." exact="Severe" post="acute respiratory syndrome coronavirus as an agent of emerging"/>
  <result pre="C., LauS. K., WooP. C., &amp;amp; YuenK. Y. (2007). Severe" exact="acute" post="respiratory syndrome coronavirus as an agent of emerging and"/>
  <result pre="LauS. K., WooP. C., &amp;amp; YuenK. Y. (2007). Severe acute" exact="respiratory" post="syndrome coronavirus as an agent of emerging and reemerging"/>
  <result pre="K., WooP. C., &amp;amp; YuenK. Y. (2007). Severe acute respiratory" exact="syndrome" post="coronavirus as an agent of emerging and reemerging infection."/>
  <result pre="Y., ZakiA. M., ZambonM., &amp;amp; ZiebuhrJ. (2013). Commentary: Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group."/>
  <result pre="ZakiA. M., ZambonM., &amp;amp; ZiebuhrJ. (2013). Commentary: Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group. Journal"/>
  <result pre="FDA-approved compound library identifies four small-molecule inhibitors of Middle East" exact="respiratory" post="syndrome coronavirus replication in cell culture. Antimicrobial Agents and"/>
  <result pre="compound library identifies four small-molecule inhibitors of Middle East respiratory" exact="syndrome" post="coronavirus replication in cell culture. Antimicrobial Agents and Chemotherapy,"/>
  <result pre="Repurposing of clinically developed drugs for treatment of Middle East" exact="respiratory" post="syndrome coronavirus infection. Antimicrobial Agents and Chemotherapy, 58(8), 4885â€&quot;4893."/>
  <result pre="of clinically developed drugs for treatment of Middle East respiratory" exact="syndrome" post="coronavirus infection. Antimicrobial Agents and Chemotherapy, 58(8), 4885â€&quot;4893. 10.1128/AAC.03036-1424841273"/>
  <result pre="Overcoming regulatory and financial hurdles in repurposing approved drugs as" exact="cancer" post="therapeutics. Frontiers in Oncology, 7, 27310.3389/fonc.2017.0027329184849 HouT., LiN., LiY.,"/>
  <result pre="H. L., WongS. S. Y., LeungS.-Y., ChanK.-H., &amp;amp; YuenK.-Y. (2005)." exact="Severe" post="acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats."/>
  <result pre="L., WongS. S. Y., LeungS.-Y., ChanK.-H., &amp;amp; YuenK.-Y. (2005). Severe" exact="acute" post="respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proceedings"/>
  <result pre="WongS. S. Y., LeungS.-Y., ChanK.-H., &amp;amp; YuenK.-Y. (2005). Severe acute" exact="respiratory" post="syndrome coronavirus-like virus in Chinese horseshoe bats. Proceedings of"/>
  <result pre="S. Y., LeungS.-Y., ChanK.-H., &amp;amp; YuenK.-Y. (2005). Severe acute respiratory" exact="syndrome" post="coronavirus-like virus in Chinese horseshoe bats. Proceedings of the"/>
  <result pre="&amp;amp; SungJ. J. Y. (2003). A major outbreak of severe" exact="acute" post="respiratory syndrome in Hong Kong. The New England Journal"/>
  <result pre="SungJ. J. Y. (2003). A major outbreak of severe acute" exact="respiratory" post="syndrome in Hong Kong. The New England Journal of"/>
  <result pre="J. Y. (2003). A major outbreak of severe acute respiratory" exact="syndrome" post="in Hong Kong. The New England Journal of Medicine,"/>
  <result pre="M. (2014). Ribavirin and interferon alfa-2a for severe Middle East" exact="respiratory" post="syndrome coronavirus infection: A retrospective cohort study. The Lancet."/>
  <result pre="(2014). Ribavirin and interferon alfa-2a for severe Middle East respiratory" exact="syndrome" post="coronavirus infection: A retrospective cohort study. The Lancet. Infectious"/>
  <result pre="respiratory syndrome coronavirus infection: A retrospective cohort study. The Lancet." exact="Infectious" post="Diseases, 14(11), 1090â€&quot;1095. 10.1016/S1473-3099(14)70920-X25278221 PriceD. J., &amp;amp; Brooks IIIC."/>
  <result pre="van MaanenK., Hidalgo-HermosoE., BoschB.-J., â€¦ KoopmansM. P. (2013). Middle East" exact="respiratory" post="syndrome coronavirus neutralising serum antibodies in dromedary camels: A"/>
  <result pre="MaanenK., Hidalgo-HermosoE., BoschB.-J., â€¦ KoopmansM. P. (2013). Middle East respiratory" exact="syndrome" post="coronavirus neutralising serum antibodies in dromedary camels: A comparative"/>
  <result pre="antibodies in dromedary camels: A comparative serological study. The Lancet" exact="Infectious" post="Diseases, 13(10), 859â€&quot;866. 10.1016/S1473-3099(13)70164-623933067 RoeD. R., &amp;amp; Cheatham IIIT."/>
  <result pre="&amp;amp; ByrareddyS. N. (2020). The epidemiology and pathogenesis of coronavirus" exact="disease" post="(COVID-19) outbreak. Journal of Autoimmunity, 109, 10243310.1016/j.jaut.2020.10243332113704 SchrodingerL. (2011)."/>
  <result pre="Ul QamarM. T., AlqahtaniS. M., AlamriM. A., &amp;amp; ChenL.-L. (2020)." exact="Structural" post="basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from"/>
  <result pre="(2012). Isolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi Arabia. The New England Journal of Medicine,"/>
  <result pre="F., &amp;amp; TanW. (2020). A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019. The New England Journal of Medicine,"/>
 </snippets>
</snippetsTree>
